Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 8, 2025

Study Completion Date

March 15, 2027

Conditions
PreeclampsiaPreeclampsia PostpartumPreeclampsia Severe or Mild
Interventions
DIAGNOSTIC_TEST

Butterfly iQ3 ultrasound system for determination of postpartum volume status

"A trained study staff member will perform point-of-care ultrasound (POCUS) of the lungs and the inferior vena cava (IVC). All POCUS assessments will be performed using either the curvilinear or phased array settings on a portable Butterfly iQ3 ultrasound system. Images obtained via the Butterfly iQ3 ultrasound system will be labeled according to the subject's unique identification number and transmitted directly to a digital study archive. The lead investigator or physician of record will review all captured ultrasound images to ensure that an appropriate therapy is selected moving forward.~Any subject who is confirmed to have 3 or more B-lines, a maximum IVC diameter above 2.0cm, or an IVC collapsibility index less than 15% on POCUS will become a candidate for diuretic therapy, which will be ordered by the patient's primary inpatient provider."

DRUG

Oral furosemide

Any subject who is confirmed to have 3 or more B-lines, a maximum IVC diameter above 2.0cm, or an IVC collapsibility index less than 15% on POCUS will become a candidate for diuretic therapy, which will be ordered by the patient's primary inpatient provider. The first cohort of 48 patients will be treated with oral furosemide 20mg daily and oral potassium chloride 40mEq daily for a total of 5-days. As patients delivered vaginally are typically discharged 2-3 days after birth and delivered via cesarean are typically discharged 4-5 days after birth, patients who have not yet completed the medication course by the time of planned discharge will be prescribed the remainder of their medications before departing the hospital.

DRUG

Intravenous furosemide

Any subject who is confirmed to have 3 or more B-lines, a maximum IVC diameter above 2.0cm, or an IVC collapsibility index less than 15% on POCUS will become a candidate for diuretic therapy, which will be ordered by the patient's primary inpatient provider. The second cohort of 48 patients will be treated with a single dose of intravenous furosemide 40mg and oral potassium chloride 40mEq on postpartum day 1.

Trial Locations (1)

92868

University of California Irvine Medical Center, Orange

All Listed Sponsors
lead

University of California, Irvine

OTHER